Recap: The Association for Research in Vision and Ophthalmology takes Seattle
ARVO attendees took a deep dive into trends and explored the near future of vision science
ARVO 2024: Trial design and increased accuracy of meibomian gland morphology measurements
At the 2024 ARVO meeting, Andrew D. Pucker, OD, PhD, presented a paper on measuring meibomian gland morphology
ARVO 2024: Mutation agnostic optogenetic programme demonstrates possible treatment for patients with severe retinal degeneration
Allen Ho, MD, presented on the 12-month results of an mutation agnostic optogenetic programme at the ARVO 2024 meeting
ARVO 2024: Predicting the efficacy of myopia control methods using 1-year data
At this year's ARVO meeting, the Eye Care Network got a glimpse at the future of paediatric myopia control research
ARVO 2024: President-elect SriniVas Sadda, MD, shares his strategies for engaging vision experts worldwide
Incoming ARVO president SriniVas R. Sadda, MD, discussed major challenges in vision science research and how annual meetings inspire innovation in ophthalmology
ARVO 2024: Reliability of contact specular microscopy in the corneal endothelium
Elias Kahan speaks about his ARVO poster, "Contact specular microscopy reliably images the same location of the corneal epithelium"
ARVO 2024: Non-invasive testing could use tear film to screen for changes in Huntington Disease
The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease
ARVO 2024: Exploring multi-ingredient oral supplements for alleviating symptoms of dry eye disease
At this year's ARVO meeting, Neda Gioia, OD, discussed the increasing patient burden of dry eye disease
ARVO 2024: Evaluating a lipid-containing eye drop for dry eye disease
Eric Donnenfeld, MD, discusses the clinical evaluation of Blink Triple Care artificial tears ahead of the 2024 ARVO meeting
ARVO 2024: Dry eye patient selection following post-hoc analysis of GOBI and MOJAVE trials
John Sheppard, MD, MSc, FACs, discusses the unique biochemical traits of perfluorohexyloctane for eye dry disease and meibomian gland dysfunction
ARVO 2024: Assessing melanocortin receptors and inflammation in the ocular space
Paul Kayne, PhD gave an onsite overview of his poster at the 2024 ARVO meeting
ARVO 2024: Imaging provides insight into the metabolic aspects of glaucoma development
Osamah Saeedi, MD, MS, discusses his poster presentation from the ARVO Imaging in the Eye conference
ARVO 2024: Children with CVI experience lower vision-specific quality of life, study results indicate
Investigators say children with cortical/cerebral visual impairment experience markedly lower vision-specific quality of life
ARVO 2024: Novel contact lens solution bolsters comfort in potential lens wear dropouts
Marjorie Rah, OD, PhD, FAAO, discussed the in-home use test of BioTrue Hydration Plus multipurpose contact lens solution (Bausch + Lomb) on patients who are considering lens dropout.
ARVO 2024: Functional microperimetric correlates of OCT structural features in AMD
At the ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Giulia Corradetti, MD about AMD
ARVO 2024: New data on diabetic retinopathy lesions from the DRCR Retina Network
Paolo Silva, MD, speaks on the effect of diabetic retinopathy lesion location and long-term risk of progression
ARVO 2024: Baruch Kuppermann, MD, PhD, discusses durability of a pan-VEGF tyrosine kinase inhibitor
Barry Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California Irvine, speaks about his ARVO poster presentation
ARVO 2024: An adaptable deep learning model for geographic atrophy segmentation
Qinqin Zhang, PhD, presented on a deep learning model for GA segmentation at this year's ARVO meeting
ARVO 2024: Insights on dry AMD and geographic atrophy from the GALE study of pegcetacoplan
At this year's ARVO meeting, Ash Abbey, MD, presented 36-month data from the GALE study of pegcetacoplan
ARVO 2024: Diabetic retinopathy risk factors in paediatric patients with Type 1 diabetes
Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy
ARVO 2024: CHAMP phase 3 trial shows myopia controlled by low-dose atropine 0.01% over 4-year course
This study also investigated the development of myopia rebound when dosing was discontinued
ARVO 2024: Taking stock of patients' nAMD experience using an activity inventory
Antonio Filipe Macedo, OD, MSc, PhD, speaks about his ARVO presentation on vision-related activity difficulties in patients with neovascular age-related macular degeneration
ARVO 2024: Using objective measures to gauge activity levels of visually-impaired children
New research findings presented at this year's ARVO meeting compare two groups of paediatric patients in Nepal
ARVO 2024: New research indicates the need for a new approach to central vision loss
Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care
ARVO 2024: Updates from the BLINK2 study on contact lens wear and axial length growth
At this year's ARVO meeting, new data from the BLINK2 study show axial growth rates after discontinuing soft multifocal contact lens wear
ARVO 2024: How delayed onset of vision impairment alters auditory distance estimation
Age of vision loss onset has a stark impact on patients’ auditory processing and sensory substitution
ARVO 2024: Murine model of multiple sclerosis demonstrates correlation between visual markers and motor-sensory deficits
Study data demonstrated a significant correlation between visual function, structure and neurological impairment in an experimental autoimmune encephalomyelitis model
ARVO 2024: Industry leaders will provide company updates and new clinical data at conference
Ahead of the meeting, several companies previewed product pipeline announcements and research data presentations
Plan your visit to Seattle: This year's ARVO meeting promises must-see programming
The meeting kicks off with symposia and an opening keynote speech from Ed Yong
ARVO 2023: Lamina cribrosa pressure and predicting structural glaucoma progression
Ronald Zambrano, lab supervisor for the advanced Ophthalmic Imaging Lab at NYU Langone, talks about lamina cribrosa pressure and predicting structural glaucoma progression at this year's ARVO meeting.